“The InSet™ 70 complements our broad portfolio of advanced shoulder implant solutions, and we are excited to bring it to market across the United States ahead of schedule,” said Rob Ball, CEO of Shoulder Innovations. “SI has a strong history of innovation, and the InSet™ 70 is another example of new technology designed to enhance the quality of care for patients and provide meaningful value to the surgeons who care for them. We look forward to seeing improved patient outcomes and long-term function with this implant.”

Indicated for use in both anatomic and reverse shoulder arthroplasty, the InSet™ 70 addresses a broad range of clinical needs, including non-inflammatory degenerative joint disease such as osteoarthritis and avascular necrosis, rheumatoid and traumatic arthritis, and correction of functional deformity. In reverse procedures, it is further indicated for irreparable cuff tears with or without arthritis, as well as for revision of other devices when sufficient bone stock remains.